{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:18:41Z","timestamp":1790857121222,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"F. Hoffmann-La Roche Ltd\/Genentech, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11523-022-00888-9","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T12:03:00Z","timestamp":1655467380000},"page":"283-293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I\/II Study"],"prefix":"10.1007","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct02639546","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tanya","family":"Trippett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Campbell Hewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnauld","family":"Verschuur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Langevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rossig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshak","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo R.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravanthi","family":"Cheeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Musib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"888_CR1","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291\u2013310.","journal-title":"Oncogene"},{"key":"888_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/path.2558","volume":"218","author":"T Forshew","year":"2009","unstructured":"Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, et al. Activation of the ERK\/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol. 2009;218:172\u201381.","journal-title":"J Pathol"},{"key":"888_CR3","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1073\/pnas.1219232110","volume":"110","author":"AJ Sievert","year":"2013","unstructured":"Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci USA. 2013;110:5957\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"888_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1586\/17474086.2013.827415","volume":"6","author":"O Vitagliano","year":"2013","unstructured":"Vitagliano O, Addeo R, D\u2019Angelo V, Indolfi C, Indolfi P, Casale F. The Bcl-2\/Bax and Ras\/Raf\/MEK\/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev Hematol. 2013;6:587\u201397.","journal-title":"Expert Rev Hematol"},{"key":"888_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","volume":"4","author":"JF Shern","year":"2014","unstructured":"Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4:216\u201331.","journal-title":"Cancer Discov"},{"key":"888_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fonc.2014.00160","volume":"4","author":"T Knight","year":"2014","unstructured":"Knight T, Irving JAE. Ras\/Raf\/MEK\/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting. Front Oncol. 2014;4:160.","journal-title":"Front Oncol"},{"key":"888_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/2211-5463.12586","volume":"9","author":"G Xie","year":"2019","unstructured":"Xie G, Wu H, Cai W, Chen M, Huang W, Yan W, et al. RDM1 promotes neuroblastoma growth through the RAS\u2013Raf\u2013MEK\u2013ERK pathway. FEBS Open Bio. 2019;9:490\u20137.","journal-title":"FEBS Open Bio"},{"key":"888_CR8","first-page":"750","volume":"19","author":"RJ Packer","year":"2017","unstructured":"Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, et al. Pediatric low-grade gliomas: Implications of the biologic era. Neuro Oncol. 2017;19:750\u201361.","journal-title":"Neuro Oncol"},{"key":"888_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s10014-019-00340-3","volume":"36","author":"K Tateishi","year":"2019","unstructured":"Tateishi K, Nakamura T, Yamamoto T. Molecular genetics and therapeutic targets of pediatric low-grade gliomas. Brain Tumor Pathol. 2019;36:74\u201383.","journal-title":"Brain Tumor Pathol"},{"key":"888_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/MOP.0000000000000717","volume":"31","author":"P de Blank","year":"2019","unstructured":"de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019;31:21\u20137.","journal-title":"Curr Opin Pediatr"},{"key":"888_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s10637-016-0374-3","volume":"34","author":"LS Rosen","year":"2016","unstructured":"Rosen LS, LoRusso P, Wee Ma W, Goldman JW, Weise A, Colevas AD, et al. A first-in-human phase I study to evaluate the MEK1\/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs. 2016;34:604\u201313.","journal-title":"Invest New Drugs"},{"key":"888_CR12","unstructured":"Cobimetinib SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cotellic-epar-product-information_en.pdf. Accessed 1 Oct 2021."},{"key":"888_CR13","unstructured":"FDA. Cotellic PI. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206192s000lbl.pdf. Accessed 1 Oct 2021."},{"key":"888_CR14","unstructured":"EMA. Cotellic EPAR summary. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic. Accessed 1 Oct 2021."},{"key":"888_CR15","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","volume":"35","author":"JR Park","year":"2017","unstructured":"Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials planning meeting. J Clin Oncol. 2017;35:2580\u20137.","journal-title":"J Clin Oncol"},{"key":"888_CR16","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2012","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2012;28:1963\u201372.","journal-title":"J Clin Oncol"},{"key":"888_CR17","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (Version 1.1). Eur J Cancer. 2009;45:228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"888_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29\u201341.","journal-title":"Biometrics"},{"key":"888_CR19","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s40262-016-0412-5","volume":"55","author":"NR Budha","year":"2016","unstructured":"Budha NR, Ji T, Musib L, Eppler S, Dresser M, Chen Y, et al. Evaluation of cytochrome P450 3A4-mediated drug\u2013drug interaction potential for cobimetinib using physiologically based pharmacokinetic modeling and simulation. Clin Pharmacokinet. 2016;55:1435\u201345.","journal-title":"Clin Pharmacokinet"},{"key":"888_CR20","unstructured":"Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Filing for Cobimetinib. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206192Orig1s000ClinPharmR.pdf. Accessed 1 Oct 2021."},{"key":"888_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/MOP.0000000000000570","volume":"30","author":"SJ Forrest","year":"2018","unstructured":"Forrest SJ, Geoerger B, Janeway KA. Precision medicine in pediatric oncology. Curr Opin Pediatr. 2018;30:17\u201324.","journal-title":"Curr Opin Pediatr"},{"key":"888_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/neuonc\/now282","volume":"19","author":"A Banerjee","year":"2017","unstructured":"Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Poussaint TY, et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: A Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 2017;19:1135\u201344.","journal-title":"Neuro Oncol"},{"key":"888_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20:1011\u201322.","journal-title":"Lancet Oncol"},{"key":"888_CR24","doi-asserted-by":"crossref","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. NFM-07. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382:1430\u201342.","DOI":"10.1056\/NEJMoa1912735"},{"key":"888_CR25","doi-asserted-by":"crossref","unstructured":"McCowage GB, Mueller S, Pratilas CA, Hargrave DR, Moertel CL, Whitlock J, et al. Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)\u2013associated plexiform neurofibroma: a phase I\/IIa study. J Clin Oncol. 2018;36(15_Suppl):10504.","DOI":"10.1200\/JCO.2018.36.15_suppl.10504"},{"key":"888_CR26","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim AR, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375:2550\u201360.","journal-title":"N Engl J Med"},{"key":"888_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ijc.31052","volume":"142","author":"MC de Gooijer","year":"2018","unstructured":"de Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O. The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018;142:381\u201391.","journal-title":"Int J Cancer"},{"key":"888_CR28","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1021\/mp500435s","volume":"11","author":"EF Choo","year":"2014","unstructured":"Choo EF, Ly J, Chan J, Shahidi-Latham SK, Messick K, Plise E, et al. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib. Mol Pharm. 2014;11:4199\u2013207.","journal-title":"Mol Pharm"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00888-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-022-00888-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00888-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T11:46:58Z","timestamp":1655898418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-022-00888-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1007\/s11523-022-00888-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"26 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by F. Hoffmann-La Roche Ltd\/Genentech, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"TT reports consultancy fees from F. Hoffmann-La Roche Ltd. HT reports lecture fees from AstraZeneca and Roche. SG reports personal fees from Bayer, EUSA Pharma, and LOXO Oncology. CR reports personal fees from Amgen, BMS, Celgene, Genentech, Inc., Novartis, Pfizer, and F. Hoffmann-La Roche Ltd. DP was an employee of F. Hoffman-La Roche Ltd. at the time of study conduct. LM was an employee of Genentech, Inc. at the time of study conduct. LRP is an employee of F. Hoffmann-La Roche Ltd. SC, KEH, CD, and RB are employees of and stock-holders in F. Hoffmann-La Roche Ltd\/Genentech, Inc. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from parents, patients, or legal representatives.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qualified researchers may request access to individual patient level data through the clinical study data request platform (\n                      \n                      ). Further details on Roche's criteria for eligible studies are available here (\n                      \n                      ). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (\n                      \n                      ).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TT and BG contributed to the conception and design of the study. All authors contributed to collection and assembly of data, and to data analysis and interpretation. All authors critically reviewed the manuscript, provided final approval, and agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}